Current Bevacizumab News and Events

Current Bevacizumab News and Events, Bevacizumab News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 7 | 255 Results
Anticancer drug may improve outcome for severe COVID-19 patients
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. The research is published in Nature Communications. (2021-02-05)

Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients
New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a 'major breakthrough' in the field. (2021-02-05)

Patients with lung cancer reduce smoking rate after enrollment in phase III clinical trial
The first comprehensive, prospective study of smoking habits in patients with non-small cell lung cancer (NSCLC) who were enrolled in a phase III early-stage trial revealed that there was a high rate of smoking reduction and cessation following study entry, according to research published today in the Journal of Thoracic Oncology. (2021-02-01)

Response to adjuvant bevacizumab among patients with resected melanoma may vary by age
Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not. (2020-10-23)

Common treatment for diabetic macular edema not effective in Black individuals
A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show. (2020-10-22)

Researchers identify genetic variants linked to toxic side effects from bevacizumab
In the largest study of its kind, researchers have found two common genetic variants that can be used to predict whether or not cancer patients might suffer severe adverse side-effects, such as high blood pressure, from the drug bevacizumab. The genome-wide association study is the largest such study in patients being treated with bevacizumab and it is to be presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (2020-10-21)

Very low-dose Avastin effective for preventing blindness in preterm infants
Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently. Results from the dose-finding study were published April 23 in JAMA Ophthalmology. The study was conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and supported by the National Eye Institute (NEI), part of the National Institutes of Health. (2020-04-23)

Levels of sBTLA proteins as potential marker of overall survival of liver cancer patients
Researchers at Osaka City University Graduate School of Medicine introduced sorafenib to patients with advanced stages of the liver cancer hepatocellular carcinoma (HCC) and measured the amount of 16 circulating soluble immune checkpoint proteins. Their data suggest that a high amount of sBTLA proteins may be a marker of overall survival in patients with HCC. (2020-03-09)

Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy
To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment. (2020-01-08)

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial
A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more aggressive treatment. (2019-12-19)

Combination of immunotherapy and VEGF inhibitor improves survival in HCC
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress. (2019-11-22)

Ovarian cancer: more women benefit from maintenance combined targeted therapy
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation. According to late breaking results of the PAOLA-1/ENGOT-ov25 trial, this approach extends progression free survival in patients with advanced ovarian cancer. (2019-09-28)

PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial. (2019-09-28)

Breaking the 'stalemate' in the most common soft tissue sarcoma in children
Rhabdomyosarcoma is the most common soft tissue sarcoma in children. A phase II clinical trial, led by Leo Mascarenhas, M.D., at Children's Hospital Los Angeles, is the first to show improved outcomes in rhabdomyosarcoma in 45 years. (2019-09-12)

Scientists track brain tumor turncoats with advanced imaging
To better understand the cells that brain tumors recruit, scientists developed advanced imaging techniques to visualize macrophages. (2019-06-25)

Identifying colorectal cancer subtypes could lead to improved treatment decisions
Identifying a metastatic colorectal cancer patient's Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. For example, Survival for CMS1 patients on bevacizumab was twice that of those on cetuximab, whereas survival for CMS2 patients on cetuximab was six months longer than for bevacizumab. (2019-06-12)

Stephenson Cancer Center physician is senior author on major study
A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer -- longer survival times plus a treatment option that causes fewer difficult side effects. (2019-05-03)

Mouse studies show minimally invasive route can accurately administer drugs to brain
In experiments in mice, Johns Hopkins researchers say they have developed a technique that facilitates the precise placement of cancer drugs at their intended targets in the brain. (2019-05-01)

Precision oncology insights revealed for colorectal cancer
Findings published in the Journal of Clinical Oncology could help define strategies to more effectively treat colorectal cancer, the second leading cause of cancer death in the United States. (2019-03-19)

Chromosomal instability may predict patients that will benefit from colorectal cancer drug
Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin). (2018-10-10)

Glioma subtypes determine how the dangerous tumors spread, evade anti-angiogenic treatment
A multi-institutional research team led by investigators at Massachusetts General Hospital and the University of California San Francisco has identified a new mechanism by which the dangerous brain tumors called gliomas develop resistance to anti-angiogenic treatment. (2018-04-27)

Training the immune system to fight ovarian cancer
A personalized cancer vaccine safely and successfully boosted immune responses and increased survival rates in patients with ovarian cancer, according to results from a pilot clinical trial. (2018-04-11)

Ludwig researchers devise and test pioneering personalized ovarian cancer vaccine
A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer. (2018-04-11)

Biomarker helps identify 'window of opportunity' for cancer chemotherapy timing
Angiogenesis, the formation of new blood vessels, is essential for tumor growth. A new study reported in The American Journal of Pathology describes a vascular stabilization biomarker that can visualize blood vessel activity, thus optimizing the timing of anticancer therapies including anti-angiogenics. (2018-04-09)

The use of immunotherapy to treat metastatic breast cancer
The Authors review immunotherapy attempts to treat metastatic breast cancer. They include a) the addition of cytokines to endocrine therapy, b) monoclonal antibodies associated to chemotherapy and c) vaccination. (2018-03-19)

Obesity may promote resistance to antiangiogenic therapy for breast cancer
A research team led by Massachusetts General Hospital investigators has found, for the first time, that obesity and obesity-related molecular factors appear to induce resistance to antiangiogenic therapy in breast cancer patients and in mouse models of the disease. (2018-03-14)

Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2
A Massachusetts General Hospital research team reports that the use of crizotinib to block a specific molecular pathway both enhanced the radiosensitivity of tumors in mouse models of NF2, allowing a reduction in radiation dosage, and inhibited the growth of cultured tumor cells from NF2 patients. (2018-02-05)

New and highly sensitive ELISA technique for bioanalysis of bevacizumab
Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC). (2018-01-31)

Bevacizumab dramatically improves severe hereditary hemorrhagic telangiectasia (HHT) associated bleeding
Patients with hereditary hemorrhagic telangiectasia (HHT) with severe bleeding, who were treated with intravenous bevacizumab, reported a marked reduction in nose bleeds and gastrointestinal bleeding and were able to stop or considerably reduce blood transfusions, resulting in significantly improved quality of life. A new study published in Mayo Clinic Proceedings provides good quality evidence for the excellent safety profile and efficacy of intravenous bevacizumab in the management of these patients. (2018-01-29)

Starving tumors: New target discovered
Actively growing tumors have a high demand for oxygen and nutrients. Therefore, they stimulate the growth of blood vessels. This process is called angiogenesis. If tumor-associated angiogenesis is suppressed, this may limit tumor growth. Scientists from the German Cancer Research Center and the European Center for Angioscience at Heidelberg University have now discovered a new target for anti-angiogenic tumor therapy (2018-01-23)

Protein analysis allows for treatment of eye-disease symptoms with existing drugs
Demonstrating the potential of precision health, a team led by a researcher at the Stanford University School of Medicine has matched existing drugs to errant proteins expressed by patients with a rare eye disease. (2017-12-21)

First line combination therapy improves progression-free survival in advanced lung cancer
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017. (2017-12-07)

Blood test could help predict skin cancer's return
Cancer Research UK scientists have discovered that testing skin cancer patients' blood for tumor DNA could help predict the chances of an aggressive cancer returning. (2017-12-05)

Study shows new second line therapy for metastatic colorectal cancer is effective and safe
A randomised trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress. (2017-11-20)

Ludwig scientists share findings at 2017 Society for Neuro-oncology Annual Meeting
Ludwig Cancer Research has released the scope of its participation at this year's Annual Meeting and Education Day of the Society for Neuro-Oncology in San Francisco, California, Nov. 16-19. (2017-11-13)

Cheaper drug could release more than £13.5 million a year within the next 5 years for other services
Doctors in the northeast of England face legal action from two of the world's largest pharmaceutical companies for offering patients with a serious eye condition the choice of a safe, effective but much cheaper drug, reports The BMJ today. (2017-10-31)

Right-sided colorectal tumors: An internal radiation advantage
For patients with colorectal cancer that has metastasized to the liver, having a primary tumor on the left side, as opposed to the right side of the colon, is known to be a significant advantage in terms of treatment response. But now a new study suggests this imbalance may be at least partially redressed. (2017-07-01)

Avastin as effective as Eylea for treating central retinal vein occlusion
Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI), part of the National Institutes of Health. After six monthly injections, treatment with either drug improved visual acuity on average from 20/100 to 20/40. (2017-05-09)

PET/CT helps predict therapy effectiveness in pediatric brain tumors
In this first ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron emission tomography/computed tomography (PET/CT) scans to determine whether bevacizumab (Avastin) treatment of diffuse intrinsic pontine glioma (DIPG) in children is likely to be effective. The study is featured in the May 2017 issue of The Journal of Nuclear Medicine. (2017-05-02)

Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. (2017-03-29)

Page 1 of 7 | 255 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.